Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S0). [1]
2026 List, S0, printed page 4 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and medical research
S48168, also called ARM210 and surlorian, is a Rycal investigated in RYR1-related myopathy. The proposed target is abnormal calcium release through the skeletal-muscle ryanodine receptor. These names identify a research compound, not evidence of general recovery benefit. [2] [3]
Early human trial
A 2024 phase 1 open-label study included six unique adults, with one participant re-enrolled, producing seven treatment enrolments. Over 29 days it primarily examined safety and pharmacokinetics. Fatigue and strength findings were exploratory, without a placebo comparison. No serious adverse events were reported; reflux and a transient glucose increase were considered possibly treatment-related. [2]
- The small, heterogeneous sample, short follow-up and unblinded design prevent firm efficacy or long-term safety conclusions.
What remains unproven
The phase 1 report disclosed NIH and commercial support, sponsor involvement and company-related author interests. A later HRA summary describes a planned randomized, blinded, placebo-controlled crossover phase 2 study in adults with autosomal-dominant RYR1-related myopathy. A study plan is not a positive result or marketing authorization. [2] [3]
What remains uncertain
- Phase 2 outcomes and current recruitment were not established in this review.
- No athletic-performance, ordinary-food or current consumer-product evidence was verified.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- Todd et al. 2024: S48168/ARM210 phase 1 RYR1-myopathy trial ↗Accessed 2026-11-10 · full_text_relevant_sections
EClinicalMedicine; DOI 10.1016/j.eclinm.2024.102433; methods, safety, discussion, funding
- UK HRA: phase 2 surlorian trial in RYR1-related myopathy ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Study summary, design and identifiers
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.